Caixin Global
@caixin
Award-winning journalism from China's most respected newsroom. App:
加入 January 2010
77 正在關注 90.8K 粉絲
Multinational drugmakers are returning to China’s centralized procurement program after rule changes gave originator medicines a second path to selection, though stronger price pressure still looms.
顯示更多
